ArticleHaematologica2016

Imatinib withdrawal syndrome and longer duration of imatinib have a close association with a lower molecular relapse after treatment discontinuation: the KID study.

Sung-Eun Lee et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.